Behçet’s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-024-02191-y ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Tadakazu Hisamatsu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Behcet Syndrome, Gastrointestinal Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferring Pharmaceuticals.
Abstract (Originalsprache)
Background
Behçet’s disease (BD) is an autoinflammatory disease that can affect multiple organs, including the gastrointestinal tract. Conventional management comprises anti-inflammatory drugs such as glucocorticoids (GCs) and/or immunomodulators that alleviate symptoms. The introduction of biological agents that target tumor necrosis factor α (TNF-α) has improved disease management. The goal of this work was to analyze the current prevalence and incidence of total BD and gastrointestinal Behçet’s disease (GIBD) in Japan, and examine treatment trends, especially regarding the use of TNF-α inhibitors (TNFαi).
Methods
We performed a retrospective descriptive observational study in which BD and GIBD demographic trends, medical treatment patterns, and reported adverse events (AEs) were assessed among patients with data recorded between 2017 and 2021 in the Japan Medical Data Center Claims Database (now JMDC Inc.).
Results
Prevalence of BD and GIBD in Japan during the observation period increased at an annual rate of + 3% and + 4%, respectively, while incidence decreased by − 5% and − 2%, with a more prominent decline in confirmed GIBD cases (− 15%). Although GCs were the most common initial treatment administered, use of TNFαi for BD and GIBD management increased by + 5.6% and + 8.1%, respectively. Severe AEs (mainly pneumonia and GI-associated AEs) were reported in 40% of patients receiving TNFαi; however, a high retention rate (of up to 80%) was observed 3 years after treatment initiation.
Conclusion
The use of TNFαi for GIBD treatment has increased in Japan in recent years. Additional research is necessary to further evaluate TNFαi effectiveness in GIBD and other BD subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
- Clinical and Translational Sciences, Ferring Pharmaceuticals, 2770, Kastrup, Denmark.
- Department of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Kanagawa, Japan. m-takeno@nms.ac.jp.
ORCID-Profile: Mitsuhiro Takeno
Förderung
- Ferring Pharmaceuticals
Zitieren
APA
Hisamatsu, T., Naganuma, M., Pinton, P., & Takeno, M. (2025). Behçet’s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02191-y
Vancouver
Hisamatsu T, Naganuma M, Pinton P, Takeno M. Behçet’s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02191-y
BibTeX
@article{Hisamatsu2025,
author = {Hisamatsu, Tadakazu and Naganuma, Makoto and Pinton, Philippe and Takeno, Mitsuhiro},
title = {Behçet’s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-024-02191-y}
}
EUVIMED